Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 956785, 6 pages
http://dx.doi.org/10.1155/2015/956785
Clinical Study

Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy

Division of Gynecology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan

Received 21 November 2014; Revised 22 January 2015; Accepted 3 February 2015

Academic Editor: Bernardo L. Rapoport

Copyright © 2015 Masakazu Abe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. G. Kris, M. Tonato, E. Bria et al., “Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy,” Supportive Care in Cancer, vol. 19, no. 1, supplement, pp. S25–S32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Basch, A. A. Prestrud, P. J. Hesketh et al., “Antiemetics: American Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 29, no. 31, pp. 4189–4198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Poli-Bigelli, J. Rodrigues-Pereira, A. D. Carides et al., “Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America,” Cancer, vol. 97, no. 12, pp. 3090–3098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. J. Schmoll, M. S. Aapro, S. Poli-Bigelli et al., “Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment,” Annals of Oncology, vol. 17, no. 6, pp. 1000–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Campos, J. R. Pereira, R. R. Reinhardt et al., “Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone,” Journal of Clinical Oncology, vol. 19, no. 6, pp. 1759–1767, 2001. View at Google Scholar · View at Scopus
  6. P. J. Hesketh, S. M. Grunberg, R. J. Gralla et al., “The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4112–4119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Navari, S. E. Gray, and A. C. Kerr, “Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial,” Journal of Supportive Oncology, vol. 9, no. 5, pp. 188–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Tan, J. Liu, X. Liu et al., “Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Navari, C. K. Nagy, and S. E. Gray, “The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy,” Supportive Care in Cancer, vol. 21, no. 6, pp. 1655–1663, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Takeshima, M. Matoda, M. Abe et al., “Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial,” Supportive Care in Cancer, vol. 22, no. 11, pp. 2891–2898, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. P. J. Hesketh, S. M. Grunberg, J. Herrstedt et al., “Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response,” Supportive Care in Cancer, vol. 14, no. 4, pp. 354–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Bymaster, K. W. Perry, D. L. Nelson et al., “Olanzapine: a basic science update,” The British Journal of Psychiatry. Supplement, no. 37, pp. 36–40, 1999. View at Google Scholar · View at Scopus
  13. B. J. Pleuvry, “Physiology and pharmacology of nausea and vomiting,” Anaesthesia and Intensive Care Medicine, vol. 4, no. 10, pp. 349–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. D. Passik, J. Lundberg, K. L. Kirsh et al., “A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain,” Journal of Pain and Symptom Management, vol. 23, no. 6, pp. 526–532, 2002. View at Publisher · View at Google Scholar · View at Scopus